Our portfolio company Sirius Medical secures growth funding from new and existing investors to further develop the Sirius Pintuition portfolio and expand international sales
Eindhoven, 4th of February 2025 – Our portfolio company Sirius Medical, a leading medtech company and market leader in oncological surgical marker navigation, has raised €10 million in funding on World Cancer Day. This investment round was led by Invest-NL and Nextgen Ventures, with support from De Groot Family Office and existing investors Brabant Development Agency (BOM), Holland Capital, Curie Capital, Team Holmium, and Sirius Medical’s team.
World Cancer Day is a poignant reminder of the ongoing fight against cancer, and this milestone reflects Sirius Medical’s commitment to enhancing cancer care. Praised by breast cancer surgeons worldwide, the Sirius Pintuition® surgical navigation platform enables simple, best-in-class wire-free localization for breast-conserving surgery in any hospital. This latest funding round empowers Sirius Medical to enhance the Sirius Pintuition system and GPSDetect™ software platform, focusing on usability and intuitiveness, and extending its applications. Additionally, the investment will substantially bolster the sales infrastructure and support expansion into new markets.
“Announcing this funding milestone on World Cancer Day underscores the urgency of our mission to improve cancer care globally,” says Bram Schermers, CEO of Sirius Medical. “This funding round, in the current fundraising environment, is a clear testament to the talent of the Sirius Medical team, and the Pintuition technology that we have developed. We are proud to continue contributing to the fight against cancer and look forward to the next phase of growth for Sirius Medical. We will have more exciting news to announce soon.”
“From Holland Capital, we have been supporting Sirius Medical for many years to bridge the notorious ‘valley of death,’” said Jan Frens van Giessel, partner at Holland Capital. “Many young companies in medical technology fail due to a lack of funding, as reported by Financieele Dagblad a few weeks ago. For investors, investing in medical technology is risky because the development and sales processes are complex, uncertain, and lengthy. We experience this at Holland Capital as well, but when a company manages to distinguish itself and achieves key technical and commercial milestones, we do everything we can to arrange financing. This is also the case with Sirius Medical.”
“We have seen Sirius Medical grow over the years into a successful med-tech scale-up, with sales in the US, UK, almost all EU countries, and Australia. We are proud of the impressive results the Sirius Medical team has achieved. We welcome the new investors, NextGen and InvestNL, so that together we can make this Dutch healthcare innovation available to women with breast cancer worldwide,” said Jan Frens van Giessel, partner at Holland Capital.
About World Cancer Day
World Cancer Day, observed on February 4th, is a global initiative to raise awareness, inspire action, and work together to reduce the impact of cancer worldwide.
About Sirius Medical
With its roots in the Netherlands Cancer Institute, Sirius Medical is dedicated to improving care for cancer patients by delivery of unsurpassed, yet affordable solutions that enable precise and efficient removal of tumors. Sirius Pintuition is precise, simple, affordable and both CE marked, and FDA cleared. Sirius Medical is rapidly expanding with over 250 centers and 35.000 procedures globally.
Holland Venture investeert enkele miljoenen in RDW Tandartsen
Amsterdam, 5 augustus 2015 - Participatiemaatschappij Holland Venture investeert enkele miljoenen in RDW Tandartsen, een tandartsengroep van zes praktijken. De praktijken van RDW Tandartsen bieden mondzorg met verschillende specialismen. De investering stelt de...
Nieuwe financieringsronde voor SigmaScreening van bestaande en nieuwe investeerders
Amsterdam, 19 juni 2015 – SigmaScreening B.V. heeft een succesvolle financieringsronde afgesloten met bestaande aandeelhouders waaronder Holland Venture en nieuwe investeerder De Friesland Zorgverzekeraar (DFZ). SigmaScreening, een spin off van het Academisch Medisch...
Holland Venture investeert in system integrator Qi ict
Amsterdam, 15 juni 2015 - Participatiemaatschappij Holland Venture investeert in system integrator Qi ict. De onderneming biedt en beheert storage, networking en security oplossingen voor complexe ICT infrastructuren. Het management en de aandeelhouders hebben zich...
Holland Venture investeert in GGZ aanbieder Zorgverlening PGZ
Amsterdam, 9 februari 2015 - Participatiemaatschappij Holland Venture investeert in Zorgverlening PGZ. Het bedrijf uit Nederweert is gericht op zorg voor jongeren en (jong)volwassenen met een psychiatrische en/of licht verstandelijke beperking. De investering stelt de...
Uniek communicatie platform voor de zorg ontvangt financiele injectie
Amsterdam, 4 februari 2015 - Met de overhandiging van een plaquette uit handen van Drechtstedenbestuurder Richard Korteland en wethouder economische zaken Jasper Mos is de investering van Holland Venture en InnovationQuarter in IQ Messenger - het nieuwe...
Holland Venture en management verkopen hun aandelen in De Ridder aan Bunzl Plc
Amsterdam, 3 oktober 2014 - Eerder deze week hebben de aandeelhouders van De Ridder de overnamecontracten getekend waarmee ze hun aandelen in De Ridder hebben verkocht aan Bunzl Plc. Het management van de Ridder blijft na overname actief bij de onderneming. De Ridder...
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.nl